vs

Side-by-side financial comparison of LIGHTPATH TECHNOLOGIES INC (LPTH) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $16.4M, roughly 1.3× LIGHTPATH TECHNOLOGIES INC). LIGHTPATH TECHNOLOGIES INC runs the higher net margin — -57.5% vs -66.3%, a 8.8% gap on every dollar of revenue. On growth, LIGHTPATH TECHNOLOGIES INC posted the faster year-over-year revenue change (120.2% vs -8.7%). Over the past eight quarters, LIGHTPATH TECHNOLOGIES INC's revenue compounded faster (45.7% CAGR vs -0.5%).

LightPath Technologies Inc designs, manufactures and distributes high-precision optical components and assemblies, including aspheric lenses, infrared optics, and fiber optic products. It serves global clients across industrial automation, aerospace, defense, medical imaging, and telecommunications sectors.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

LPTH vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.3× larger
LUNG
$20.6M
$16.4M
LPTH
Growing faster (revenue YoY)
LPTH
LPTH
+128.9% gap
LPTH
120.2%
-8.7%
LUNG
Higher net margin
LPTH
LPTH
8.8% more per $
LPTH
-57.5%
-66.3%
LUNG
Faster 2-yr revenue CAGR
LPTH
LPTH
Annualised
LPTH
45.7%
-0.5%
LUNG

Income Statement — Q2 FY2026 vs Q1 FY2026

Metric
LPTH
LPTH
LUNG
LUNG
Revenue
$16.4M
$20.6M
Net Profit
$-9.4M
$-13.7M
Gross Margin
36.8%
77.9%
Operating Margin
-52.6%
-40.9%
Net Margin
-57.5%
-66.3%
Revenue YoY
120.2%
-8.7%
Net Profit YoY
-260.1%
5.5%
EPS (diluted)
$-0.20
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LPTH
LPTH
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$16.4M
$22.6M
Q3 25
$15.1M
$21.5M
Q2 25
$12.2M
$23.9M
Q1 25
$9.2M
$22.5M
Q4 24
$7.4M
$23.8M
Q3 24
$8.4M
$20.4M
Q2 24
$8.6M
$20.8M
Net Profit
LPTH
LPTH
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$-9.4M
$-10.4M
Q3 25
$-2.9M
$-14.0M
Q2 25
$-7.1M
$-15.2M
Q1 25
$-3.6M
$-14.4M
Q4 24
$-2.6M
$-13.2M
Q3 24
$-1.6M
$-14.1M
Q2 24
$-2.4M
$-15.3M
Gross Margin
LPTH
LPTH
LUNG
LUNG
Q1 26
77.9%
Q4 25
36.8%
77.6%
Q3 25
29.8%
74.7%
Q2 25
22.0%
72.1%
Q1 25
29.1%
72.5%
Q4 24
26.0%
74.0%
Q3 24
33.9%
73.7%
Q2 24
29.2%
73.7%
Operating Margin
LPTH
LPTH
LUNG
LUNG
Q1 26
-40.9%
Q4 25
-52.6%
-43.8%
Q3 25
-16.6%
-66.9%
Q2 25
-38.0%
-62.0%
Q1 25
-36.3%
-64.6%
Q4 24
-33.5%
-56.5%
Q3 24
-16.4%
-69.3%
Q2 24
-25.6%
-75.2%
Net Margin
LPTH
LPTH
LUNG
LUNG
Q1 26
-66.3%
Q4 25
-57.5%
-46.1%
Q3 25
-19.2%
-64.9%
Q2 25
-57.8%
-63.6%
Q1 25
-39.1%
-64.1%
Q4 24
-35.2%
-55.4%
Q3 24
-19.3%
-69.4%
Q2 24
-27.3%
-73.7%
EPS (diluted)
LPTH
LPTH
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-0.20
$-0.25
Q3 25
$-0.07
$-0.34
Q2 25
$0.19
$-0.38
Q1 25
$-0.44
$-0.36
Q4 24
$-0.07
$-0.33
Q3 24
$-0.04
$-0.36
Q2 24
$-0.15
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LPTH
LPTH
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$73.6M
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$77.9M
$45.8M
Total Assets
$148.6M
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LPTH
LPTH
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$73.6M
$69.8M
Q3 25
$76.5M
Q2 25
$4.9M
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
LPTH
LPTH
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$535.0K
$37.2M
Stockholders' Equity
LPTH
LPTH
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$77.9M
$54.1M
Q3 25
$21.4M
$60.0M
Q2 25
$15.6M
$69.1M
Q1 25
$15.7M
$77.7M
Q4 24
$26.7M
$85.8M
Q3 24
$29.4M
$93.9M
Q2 24
$30.2M
$101.2M
Total Assets
LPTH
LPTH
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$148.6M
$129.3M
Q3 25
$87.3M
$138.3M
Q2 25
$81.5M
$147.2M
Q1 25
$81.4M
$150.7M
Q4 24
$45.8M
$162.8M
Q3 24
$48.4M
$167.4M
Q2 24
$48.1M
$172.6M
Debt / Equity
LPTH
LPTH
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.02×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LPTH
LPTH
LUNG
LUNG
Operating Cash FlowLast quarter
$2.8M
Free Cash FlowOCF − Capex
$2.0M
FCF MarginFCF / Revenue
12.0%
Capex IntensityCapex / Revenue
5.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-6.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LPTH
LPTH
LUNG
LUNG
Q1 26
Q4 25
$2.8M
$-7.1M
Q3 25
$-1.1M
$-8.2M
Q2 25
$-2.6M
$-3.9M
Q1 25
$-3.2M
$-13.2M
Q4 24
$-737.4K
$-6.7M
Q3 24
$-1.7M
$-7.2M
Q2 24
$64.7K
$-5.8M
Free Cash Flow
LPTH
LPTH
LUNG
LUNG
Q1 26
Q4 25
$2.0M
$-7.1M
Q3 25
$-1.2M
$-8.3M
Q2 25
$-3.3M
$-4.0M
Q1 25
$-3.7M
$-13.5M
Q4 24
$-817.8K
$-6.8M
Q3 24
$-1.8M
$-7.7M
Q2 24
$-225.5K
$-6.2M
FCF Margin
LPTH
LPTH
LUNG
LUNG
Q1 26
Q4 25
12.0%
-31.4%
Q3 25
-8.1%
-38.4%
Q2 25
-27.3%
-16.6%
Q1 25
-40.0%
-60.0%
Q4 24
-11.0%
-28.8%
Q3 24
-21.2%
-37.6%
Q2 24
-2.6%
-30.0%
Capex Intensity
LPTH
LPTH
LUNG
LUNG
Q1 26
Q4 25
5.3%
0.1%
Q3 25
0.5%
0.4%
Q2 25
5.6%
0.2%
Q1 25
4.6%
1.3%
Q4 24
1.1%
0.5%
Q3 24
0.9%
2.0%
Q2 24
3.4%
2.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LPTH
LPTH

Other$7.9M48%
Infrared Components$5.0M31%
Visible Components$3.4M21%

LUNG
LUNG

Segment breakdown not available.

Related Comparisons